ReWalk Robotics (NASDAQ:LFWD) Earns Buy Rating from HC Wainwright

ReWalk Robotics (NASDAQ:LFWD)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $13.00 price target on the stock.

ReWalk Robotics Stock Down 4.5 %

LFWD traded down $0.09 during midday trading on Wednesday, hitting $1.85. 8,625 shares of the company were exchanged, compared to its average volume of 42,945. ReWalk Robotics has a 1-year low of $1.85 and a 1-year high of $9.10. The firm’s 50 day moving average price is $2.79 and its 200-day moving average price is $3.69.

ReWalk Robotics (NASDAQ:LFWD) last announced its earnings results on Thursday, August 15th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.03. The firm had revenue of $6.71 million for the quarter, compared to the consensus estimate of $6.71 million. ReWalk Robotics had a negative return on equity of 43.02% and a negative net margin of 77.21%. During the same period in the previous year, the business earned ($0.35) EPS. On average, analysts anticipate that ReWalk Robotics will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ReWalk Robotics stock. Dimensional Fund Advisors LP acquired a new stake in ReWalk Robotics Ltd. (NASDAQ:LFWD) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned 0.16% of ReWalk Robotics at the end of the most recent reporting period. 26.76% of the stock is currently owned by institutional investors.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.